Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53
暂无分享,去创建一个
[1] G. Dreyfuss,et al. Specific binding of heterogeneous ribonucleoprotein particle protein K to the human c-myc promoter, in vitro. , 1993, The Journal of biological chemistry.
[2] J. Hershey,et al. The p34 cdc2 -related Cyclin-dependent kinase 11 Interacts with the p47 Subunit of Eukaryotic Initiation Factor 3 during Apoptosis* , 2003, The Journal of Biological Chemistry.
[3] G I Murray,et al. Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer , 2006, British Journal of Cancer.
[4] A. Sakurada,et al. hnRNP B1 protein may be a possible prognostic factor in squamous cell carcinoma of the lung. , 2003, Lung cancer.
[5] Stephen P. Jackson,et al. hnRNP K: An HDM2 Target and Transcriptional Coactivator of p53 in Response to DNA Damage , 2005, Cell.
[6] J. Minna,et al. Monoclonal antibodies that distinguish non-small cell from small cell lung cancer. , 1983, Journal of immunology.
[7] M. Mandal,et al. Growth Factors Regulate Heterogeneous Nuclear Ribonucleoprotein K Expression and Function* , 2001, The Journal of Biological Chemistry.
[8] D. Perrotti,et al. From mRNA Metabolism to Cancer Therapy: Chronic Myelogenous Leukemia Shows the Way , 2007, Clinical Cancer Research.
[9] N. Tjandra,et al. High precision solution structure of the C-terminal KH domain of heterogeneous nuclear ribonucleoprotein K, a c-myc transcription factor. , 1999, Journal of molecular biology.
[10] L. Dwyer-Nield,et al. Differential Expression and Localization of the mRNA Binding Proteins, AU‐Rich Element mRNA Binding Protein (AUF1) and Hu Antigen R (HuR), in Neoplastic Lung Tissue , 2000, Molecular carcinogenesis.
[11] M. Tsao,et al. Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. , 1996, The American journal of pathology.
[12] J. Hershey,et al. Decreased expression of eukaryotic initiation factor 3f deregulates translation and apoptosis in tumor cells , 2006, Oncogene.
[13] A. Bhattacharyya,et al. Loss of the eukaryotic initiation factor 3f in pancreatic cancer , 2008, Molecular carcinogenesis.
[14] A. Maitra,et al. Pancreatic Carcinogenesis , 2008, Pancreatology.
[15] Galina Selivanova,et al. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. , 2009, Cancer cell.
[16] W. Loging,et al. Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53 , 1999, Oncogene.
[17] F. Real,et al. Comparative analysis of mutations in the p53 and K‐ras genes in pancreatic cancer , 1994, International journal of cancer.
[18] S. Fukuda,et al. Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer , 2006, Proteomics.
[19] M. Zvelebil,et al. Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons , 2004, Oncogene.
[20] F. Mancini,et al. MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. , 2007, Molecular cell.
[21] J. Ostrowski,et al. Nuclear shift of hnRNP K protein in neoplasms and other states of enhanced cell proliferation , 2003, British Journal of Cancer.
[22] E. Schmidt,et al. hnRNP K Binds a Core Polypyrimidine Element in the Eukaryotic Translation Initiation Factor 4E (eIF4E) Promoter, and Its Regulation of eIF4E Contributes to Neoplastic Transformation , 2005, Molecular and Cellular Biology.
[23] E. Małecka-Panas,et al. Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. , 2006, Medical science monitor : international medical journal of experimental and clinical research.
[24] D. Gewirtz. Growth arrest and cell death in the breast tumor cell in response to ionizing radiation and chemotherapeutic agents which induce DNA damage , 2000, Breast Cancer Research and Treatment.
[25] Graeme I Murray,et al. The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. , 2006, Biochimica et biophysica acta.
[26] David Levens,et al. Heterogeneous nuclear ribonucleoprotein K is a transcription factor , 1996, Molecular and cellular biology.
[27] Kavita Shah,et al. ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation , 2001, Nature Cell Biology.
[28] P. Byrd,et al. The interaction of the hnRNP family member E1B‐AP5 with p53 , 2005, FEBS letters.
[29] G. Murray,et al. Mortalin is over‐expressed by colorectal adenocarcinomas and correlates with poor survival , 2005, The Journal of pathology.
[30] Jerzy Ostrowski,et al. hnRNP K: One protein multiple processes , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.
[31] J. Ostrowski,et al. Characterization of hnRNP K protein-RNA interactions. , 2004, Journal of molecular biology.
[32] M. Tsao,et al. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. , 2000, The American journal of pathology.
[33] R. Young,et al. The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. , 2007, Experimental cell research.
[34] M. Tockman,et al. Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] S. Vicent,et al. Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. , 2003, Lung cancer.
[36] M. Mikuła,et al. Landscape of the hnRNP K protein–protein interactome , 2006, Proteomics.
[37] G. Stark,et al. Hdm2 Nuclear Export, Regulated by Insulin-like Growth Factor-I/MAPK/p90Rsk Signaling, Mediates the Transformation of Human Cells* , 2006, Journal of Biological Chemistry.
[38] J M Bujnicki,et al. Editing of hnRNP K protein mRNA in colorectal adenocarcinoma and surrounding mucosa , 2006, British Journal of Cancer.
[39] Rajendra K. Sharma,et al. Identification of the SRC pyrimidine-binding protein (SPy) as hnRNP K: implications in the regulation of SRC1A transcription. , 2003, Nucleic acids research.
[40] Y. Fukami,et al. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells , 2006, Journal of Cell Science.
[41] H. Leffers,et al. Identification, molecular cloning, expression and chromosome mapping of a family of transformation upregulated hnRNP-K proteins derived by alternative splicing. , 1994, Journal of molecular biology.